Navigation Links
Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
Date:11/6/2008

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, Acetavance(TM) (intravenous acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter-related infections. For more information about Cadence's pipeline, visit http://www.cadencepharm.com.

Forward-Looking Statements

Statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "expects," "anticipates," "plans," "will," and "assuming," and similar expressions, are intended to identify forward-looking statements, and are based on Cadence's current beliefs and expectations. Forward-looking statements include statements regarding: the timeframes in which the company anticipates filing submissions to regulatory authorities seeking marketing authorizations for its product candidates; and the timeframes in which Cadence expects to complete and announce the results of clinical trials of its product candidates. The inclusion of forward-looking statements should not be regarded as a representation by Cadence that any of its plans will be achieved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in the company's business, including, without limitation: the FDA may require Cadence to complete additional clinical, non-clinical or other requirements prior to the submission or the approval of NDAs for its product candidates; clinical trials may produce negative or inconclusive results, or may be inconsistent with previously conducted clinical trials; the FDA may not agree with changes in the statisti
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
2. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
4. Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...K, Nov. 20 ,, Reportlinker.com ...ilable in its catalogue. ,, Global Markets for...portlinker.com/p0164741/Global-Markets-for-Breast-...;utm_medium=pr&utm_campaign=prnewswire ,,...udes the spring loaded core needle market and vacu...
(Date:11/20/2009)...ss. and LONDON, Nov. 20 ... announced that it has received 510(k) clearance f...d CE Mark approval to market its WallFlex® Fu...malignant esophageal strictures (obstructions) cau...esectable esophageal cancer. ,, (Photo: http...
(Date:11/20/2009)...MEETING, Pa., Nov. 20 I...at questions why currently available medications d...g ignored, ECRI Institute, an independent nonprofi...nce on Finasteride for Prevention of Prostate Can...009, New York Times article, " Drugs to Deter So...
Breaking Medicine Technology:Reportlinker Adds Global Markets for Breast Biopsy Devices 2009 2Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 2Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 3Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 4ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 2ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 3Blue Cross Blue Shield of Massachusetts and Atrius Health Sign Alternative Quality Contract 52114 1Blue Cross Blue Shield of Massachusetts and Atrius Health Sign Alternative Quality Contract 52114 2Blue Cross Blue Shield of Massachusetts and Atrius Health Sign Alternative Quality Contract 52114 3Blue Cross Blue Shield of Massachusetts and Atrius Health Sign Alternative Quality Contract 52114 4New e p t 28R 29 BabyCenter 28R 29 Fertility Report Reveals 70 Percent of Moms Want Tighter Regulation on In Vitro Fertilization 52112 1New e p t 28R 29 BabyCenter 28R 29 Fertility Report Reveals 70 Percent of Moms Want Tighter Regulation on In Vitro Fertilization 52112 2New e p t 28R 29 BabyCenter 28R 29 Fertility Report Reveals 70 Percent of Moms Want Tighter Regulation on In Vitro Fertilization 52112 3New e p t 28R 29 BabyCenter 28R 29 Fertility Report Reveals 70 Percent of Moms Want Tighter Regulation on In Vitro Fertilization 52112 4Labopharm receives complete response letter from the U S FDA for novel antidepressant 52110 1Labopharm receives complete response letter from the U S FDA for novel antidepressant 52110 2Labopharm receives complete response letter from the U S FDA for novel antidepressant 52110 3
... GENEVA--(BUSINESS WIRE)--Jul 11,2007 - New infor...velopment program for Plasmin (Human), TAL-05-0001...,(http://www.talecris.com) this week at the XXIst ...is (ISTH) Congress in Geneva,Switzerland. The inf...ng research and development of Plasmin as a potent...
...)--Jul 11, 2007 - BioSante,Pharmaceuticals, Inc. (...monstrating that its calcium phosphate (CaP),nanop...erve as an,effective vaccine adjuvant for the deve...an flu, widely known as bird flu., The new results...ibition assay (HAI), which showed the clear adjuva...
Other Medicine Technology:New Information on the Potential of Plasmin Shared at ISTH Congress 2New Information on the Potential of Plasmin Shared at ISTH Congress 3New Information on the Potential of Plasmin Shared at ISTH Congress 4BioSante Pharmaceuticals Announces New Findings for Potential Bird,Flu Vaccine 2BioSante Pharmaceuticals Announces New Findings for Potential Bird,Flu Vaccine 3BioSante Pharmaceuticals Announces New Findings for Potential Bird,Flu Vaccine 4
(Date:11/20/2009)... , WASHINGTON, Nov. 20 /PRNewswire-USNew... Bishops urged the Senate to make essential change... federal law on abortion funding and conscience pr...e for immigrants and include strong provisions for...the Senate health care bill an "enormous disappoin...
(Date:11/20/2009)... , MADISON, N.J., Nov. 20 /PRNewswire-Firs...uenza virus may have peaked in late October, but t...source of illness in all age groups, including the...ostics Incorporated (NYSE: DGX ), the world,s le...and services. ,, In its most recent Quest Diag...
(Date:11/20/2009)... , HAIFA, Israel, November 20 /PRNewsw...orp. (CVSL.OB), http://www.CVSLMEDICAL.COM , a le... technology, today announced that,the company,s Bo...plications,in Europe, Canada and the Far East for ...re" applicable for all angioplasty (PCTA) procedur...
(Date:11/20/2009)... , NEW YORK, Nov. 20 /PRNewswire-FirstCa...nounced that it will broadcast Doctor Radio Rep...ams , an in-depth special hosted by veteran journa...m.com/cgi-bin/prnh/20080819/NYTU044LOGO ) ,, D...now About Mammograms will air November 21 live ...
(Date:11/20/2009)...pot blood pressure readings in children with chron...n even during doctor,s office visits increasing ...ng to research from Johns Hopkins Children,s Cente... appears online in the Journal of American Society...ressure measurements obtained during regular docto...
Breaking Medicine News(10 mins):Health News:U.S. Bishops Voice Disappointment in Abortion-Funding Provisions in Senate Health Bill, Urge Better Care for Immigrants and Affordability 2Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 2Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 3Health News:Cardio Vascular Medical Device to Apply for Additional Patents in Europe, Canada and Far East 2Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 2Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 3Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 4Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 5Health News:High blood pressure easy to miss in children with kidney disease 2
...d IRVINE, Calif., May 18 /PRNewswire-FirstCall/ ...502) and IDM Pharma, Inc. (Nasdaq: IDMI ) today ...olly-owned subsidiary of Takeda (Takeda America), ...a wholly-owned subsidiary to effect that transacti...
...lth supplements product, helps slow and repair som...ens as we age , , MIAMI, May 18 RevGenetics anno...-based telomere health supplements , Astral... represent biomarkers of human aging and disease."...
...y-coding genes directly into muscles , , S... of an AIDS vaccine that might actually work, rese...gainst infection with simian immunodeficiency viru... Typically, vaccines are aimed at ramping up the i...
... research suggests that patients newly diagnosed w...course of the sleep aid, eszopiclone, when beginni...apy, are more adherent with therapy in six months....leads to multiple adverse effects on health and qu...
... Veronica De La Cruz is turning to the power of s...t to overcome healthcare red tape and save the lif... a heart transplant. , La...has turned into a major grassroots campaign throug...
... High-Tech Yet Simple Device "Rewires" ...ng , Haifa, Israel (PRWEB...ty" has a whole new meaning for people with ...e, represents a significant advance for Cerebral P...
Other Medicine News:Health News:Takeda to Acquire IDM Pharma, Adding MEPACT(R) (Mifamurtide), the First Treatment Approved for Osteosarcoma in More Than 20 Years, to Its Oncology Franchise 2Health News:Takeda to Acquire IDM Pharma, Adding MEPACT(R) (Mifamurtide), the First Treatment Approved for Osteosarcoma in More Than 20 Years, to Its Oncology Franchise 3Health News:Takeda to Acquire IDM Pharma, Adding MEPACT(R) (Mifamurtide), the First Treatment Approved for Osteosarcoma in More Than 20 Years, to Its Oncology Franchise 4Health News:Takeda to Acquire IDM Pharma, Adding MEPACT(R) (Mifamurtide), the First Treatment Approved for Osteosarcoma in More Than 20 Years, to Its Oncology Franchise 5Health News:Takeda to Acquire IDM Pharma, Adding MEPACT(R) (Mifamurtide), the First Treatment Approved for Osteosarcoma in More Than 20 Years, to Its Oncology Franchise 6Health News:RevGenetics Releases Its New Science-Based Telomere Health Supplement Formulation for DNA and Chromosome Health 2Health News:RevGenetics Releases Its New Science-Based Telomere Health Supplement Formulation for DNA and Chromosome Health 3Health News:RevGenetics Releases Its New Science-Based Telomere Health Supplement Formulation for DNA and Chromosome Health 4Health News:Vaccine Shields Monkeys From Simian Form of HIV 2Health News:Vaccine Shields Monkeys From Simian Form of HIV 3Health News:2-week course of sleep aid increases CPAP adherence in OSA patients at 6 months 2Health News:Twitter Boosts CNN Reporter's Fight to Save Her Brother's Life 2Health News:Twitter Boosts CNN Reporter's Fight to Save Her Brother's Life 3Health News:New Hope for Walking Normally, Living Better With Cerebral Palsy 2
RIDASCREEN Anti-RSV IgA Assay
SAS RSV Test Kit
ImmunoCard STAT!® RSV
ImmunoCard STAT!® RSV PLUS
Medicine Products: